JPM 2024 Illumina-1704902051.pdf

1、 2024 Illumina,Inc.All rights reserved.CEO,IlluminaJacob Thaysen,Ph.D.42nd Annual J.P.Morgan Healthcare ConferenceJanuary 9,2024Note Regarding GRAILThe European Commission issued a decision to prohibit our acquisition of GRAIL in September 2022,and has adopted an order requiring Illumina and GRAIL t

2、o be held and operated as distinct and separate entities.Compliance with the order is monitored by an independent Monitoring Trustee.While the order is in place,Illumina and GRAIL are not permitted to share confidential business information except in cases in which a legal requirement to obtain such

3、 information applies or is necessary in connection with our divestment of GRAIL,and GRAIL must be run independently and exclusively in the best interests of GRAIL.Commercial interactions between the two companies must be undertaken at arms length.2Forward Looking StatementsThis release may contain f

4、orward-looking statements that involve risks and uncertainties.Among the important factors to which our business is subject that could cause actual results to differ materially from those in any forward-looking statements are:(i)challenges inherent in developing,manufacturing,and launching new produ

5、cts and services,(ii)our ability to further develop and commercialize our instruments,consumables,and products;(iii)the European Commissions prohibition of our acquisition of GRAIL,and the restorative measures imposed upon us that prohibit our integration of GRAIL;(iv)the risk that disruptions from

6、the consummation of our acquisition of GRAIL or any associated legal or regulatory proceedings or obligations will harm our business,including current plans and operations;(vi)our ability to timely divest GRAIL,and the risk that the terms of divestment are materially worse than the terms on which we